Finch Therapeutics Group, Inc. FNCH


Sector:

Healthcare

Industry:

Biotechnology

Description:

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Recent Quarter:

2024-08-13

Upcoming Quarter:

N/A

Annual Reports

Date2024-04-26
Revenue 107,000
Net Income -74,754,000
EPS -46.59
Basic Shares 1,604,549
Diluted Shares 1,604,549
Report Link
Date2023-03-23
Revenue 861,000
Net Income -113,699,000
EPS -71.52
Basic Shares 1,589,721
Diluted Shares 1,589,721
Report Link
Date2022-03-31
Revenue 18,532,000
Net Income -55,859,000
EPS -35.27
Basic Shares 1,583,739
Diluted Shares 1,583,739
Report Link
Date2020-12-31
Revenue 7,719,000
Net Income -39,248,000
EPS -24.39
Basic Shares 1,609,013
Diluted Shares 1,609,013
Report Link
Date2019-12-31
Revenue 10,154,000
Net Income -20,406,000
EPS -12.68
Basic Shares 1,609,013
Diluted Shares 1,609,013
Report Link

Annual Ratios

Date2023-12-31
PE -0.08
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.20
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -8.48
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -26.22
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -50.43
Dividend Yield 0.00
Payout Ratio: 0.000%

Quarterly Reports

Date2024-08-13
Revenue 0
Net Income -4,834,000
EPS -3.01
Basic Shares 1,605,763
Diluted Shares 1,605,763
Report Link
Date2024-05-10
Revenue 0
Net Income -3,876,000
EPS -2.41
Basic Shares 1,605,763
Diluted Shares 1,605,763
Report Link
Date2024-04-26
Revenue 2,845,000
Net Income -3,041,000
EPS -1.89
Basic Shares 1,605,763
Diluted Shares 1,605,763
Report Link
Date2023-11-08
Revenue 0
Net Income -2,416,000
EPS -1.51
Basic Shares 1,604,967
Diluted Shares 1,604,967
Report Link
Date2023-08-10
Revenue 0
Net Income -6,950,000
EPS -4.33
Basic Shares 1,604,795
Diluted Shares 1,604,795
Report Link
Date2023-05-10
Revenue 107,000
Net Income -63,939,000
EPS -39.89
Basic Shares 1,602,851
Diluted Shares 1,602,851
Report Link
Date2023-03-23
Revenue 8,000
Net Income -26,322,000
EPS -16.48
Basic Shares 1,597,610
Diluted Shares 1,597,610
Report Link
Date2022-11-10
Revenue 138,000
Net Income -40,110,000
EPS -25.21
Basic Shares 1,590,936
Diluted Shares 1,590,936
Report Link
Date2022-08-11
Revenue 361,000
Net Income -22,771,000
EPS -14.36
Basic Shares 1,585,878
Diluted Shares 1,585,978
Report Link
Date2022-05-16
Revenue 354,000
Net Income -24,554,000
EPS -15.5
Basic Shares 1,584,297
Diluted Shares 1,584,297
Report Link
Date2022-03-31
Revenue 806,000
Net Income -19,055,000
EPS -12.04
Basic Shares 1,583,056
Diluted Shares 1,583,056
Report Link
Date2021-11-10
Revenue 11,343,000
Net Income -9,955,000
EPS -6.29
Basic Shares 1,581,505
Diluted Shares 1,581,505
Report Link
Date2021-08-10
Revenue 2,830,000
Net Income -15,169,000
EPS -9.6
Basic Shares 1,579,328
Diluted Shares 1,579,328
Report Link
Date2021-05-13
Revenue 3,553,000
Net Income -13,981,000
EPS -29.89
Basic Shares 467,775
Diluted Shares 467,775
Report Link
Date2020-12-31
Revenue 1,807,000
Net Income -13,091,000
EPS -46.85
Basic Shares 279,409
Diluted Shares 279,409
Report Link
Date2020-09-30
Revenue 1,771,000
Net Income -10,090,000
EPS -36.65
Basic Shares 275,284
Diluted Shares 275,284
Report Link
Date2020-06-30
Revenue 2,349,000
Net Income -8,259,000
EPS -30.71
Basic Shares 268,977
Diluted Shares 268,977
Report Link
Date2020-03-31
Revenue 1,792,000
Net Income -7,901,000
EPS -30.13
Basic Shares 262,241
Diluted Shares 262,241
Report Link

Quarterly Ratios

Date2024-06-30
PE -0.11
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2024-03-31
PE -0.26
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-12-31
PE -0.48
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -0.86
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -0.49
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -0.07
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.22
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -0.50
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -1.48
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -2.43
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -6.21
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -15.49
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -10.99
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -4.05
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -3.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE -4.36
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -5.21
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -5.31
Dividend Yield 0.00
Payout Ratio: 0.000%

RSI:

50.32

Price:

$11.74

Market Cap:

18,848,411

EPS TTM:

-8.82

PE Ratio:

-1.33

PEPSG:

NaN

Fwd PE:

NaN

Volume:

3,968

2 Year Price Change

0.435

Index 2 Year Price Change

1.523

5 Year Price Change

No Price 5 Years Ago

Index 5 Year Price Change

1.917

PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.

Revenue

Net Income

EPS

Shares

News

Press Releases

Notable Earnings

Please select an option: